These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Positron-emission tomographic studies of the brain in parkinsonism patients]. Berezhkova LV Zh Nevrol Psikhiatr Im S S Korsakova; 1995; 95(6):93-7. PubMed ID: 8788992 [No Abstract] [Full Text] [Related]
5. PET studies of the dopaminergic system. A review. Lenzi GL; Perani D; Fazio F J Nucl Med Allied Sci; 1990; 34(1):1-9. PubMed ID: 2200859 [No Abstract] [Full Text] [Related]
8. The detection of preclinical Parkinson's disease: what is the role of positron emission tomography? Sawle GV Mov Disord; 1993 Jul; 8(3):271-7. PubMed ID: 8341290 [TBL] [Abstract][Full Text] [Related]
9. Different cerebral metabolism between parkinsonian rigidity and hyperkinesia (DID, chorea, dystonia). A PET study. Hirato M; Horikoshi S; Kawashima Y; Satake K; Shibazaki T; Ohye C Adv Neurol; 1993; 60():511-4. PubMed ID: 8420180 [No Abstract] [Full Text] [Related]
11. [Positron emission tomography and basal ganglia functions]. Kato M No To Shinkei; 1990 May; 42(5):450-60. PubMed ID: 2206633 [No Abstract] [Full Text] [Related]
12. PET and movement disorders. Brooks DJ; Frackowiak RS J Neurol Neurosurg Psychiatry; 1989 Jun; Suppl(Suppl):68-77. PubMed ID: 2666580 [TBL] [Abstract][Full Text] [Related]
13. Dopamine D1 and D2 receptors in Parkinson's disease and striatonigral degeneration determined by PET. Shinotoh H; Hirayama K; Tateno Y Adv Neurol; 1993; 60():488-93. PubMed ID: 8420176 [No Abstract] [Full Text] [Related]
14. Glucose metabolism and dopamine PET correlates in a patient with myotonic dystrophy type 2 and parkinsonism. Sansone V; Meola G; Perani D; Fazio F; Garibotto V; Cotelli M; Cotelli M; Vitelli E J Neurol Neurosurg Psychiatry; 2006 Mar; 77(3):425-6. PubMed ID: 16484664 [No Abstract] [Full Text] [Related]
15. Placebos in the brain. Harv Ment Health Lett; 2002 Jun; 18(12):8. PubMed ID: 12079811 [No Abstract] [Full Text] [Related]
16. [Current status of nuclear neuroimaging]. Kuwabara Y Fukuoka Igaku Zasshi; 2003 Feb; 94(2):26-30. PubMed ID: 12728544 [No Abstract] [Full Text] [Related]
17. [L-18F-dopa-PET in Parkinson-plus syndromes for the detection of a disordered presynaptic dopaminergic function]. Cordes M; Snow BJ; Takahashi H; Schofield P; Cooper S; Sossi V; Morrison S; Calne DB Nuklearmedizin; 1992 Mar; 31(2):43-7. PubMed ID: 1565570 [TBL] [Abstract][Full Text] [Related]
18. Regional kinetics of [11C]methylspiperone in the brain studied by positron emission tomography in patients with Parkinson's disease. Hägglund J; Aquilonius SM; Bergström K; Eckernäs SA; Hartvig P; Lundqvist H; Långström B; Malmborg P; Någren K Adv Neurol; 1987; 45():99-101. PubMed ID: 2950732 [No Abstract] [Full Text] [Related]
19. PET studies in psychiatry: validity, accuracy and future. Vallabhajosula S; Buchsbaum M J Nucl Med; 1994 Jan; 35(1):24-6. PubMed ID: 8271055 [No Abstract] [Full Text] [Related]